Patents Assigned to Sirna Therapeutics, Inc.
  • SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
    Publication number: 20150299696
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: April 26, 2013
    Publication date: October 22, 2015
    Applicant: Sirna Therapeutics, Inc.
    Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20150267200
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: James McSwiggen, Leonid Beigelman, Chandra Vargeese
  • Segmented micro RNA mimetics
    Patent number: 9096850
    Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: August 4, 2015
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
  • Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
    Patent number: 9067882
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: June 30, 2015
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Gregory L. Beutner
  • Low molecular weight cationic lipids for oligonucleotide delivery
    Patent number: 9062021
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: June 23, 2015
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Brian W. Budzik, Steven L. Colletti, Jennifer R. Davis, Ivory D. Hills, Darla Danile Seifried, Matthew G. Stanton
  • Amino alcohol cationic lipids for oligonucleotide delivery
    Patent number: 9044512
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that is more efficacious than traditional cationic lipids. The present invention employs amino alcohols to enhance the efficiency of in vivo delivery of siRNA.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: June 2, 2015
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Brian W. Budzik, Steven L. Colletti, Darla Danile Seifried, Matthew G. Stanton, Lu Tian
  • RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
    Patent number: 9029341
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of HBV gene expression and/or activity, and/or modulate a HBV gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against HBV gene expression.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: May 12, 2015
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Steve Bartz, Duncan Brown, Michael Robinson
  • Low molecular weight cationic lipids for oligonucleotide delivery
    Patent number: 9029590
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: May 12, 2015
    Assignee: SIRNA Therapeutics, Inc.
    Inventors: Steven L. Colletti, Matthew G. Stanton
  • Low molecular weight cationic lipids for oligonucleotide delivery
    Patent number: 9029604
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: May 12, 2015
    Assignee: Sirna Therapeutics, Inc.
    Inventors: John A. Bawiec, III, Zhengwu J. Deng
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20150105445
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: August 13, 2014
    Publication date: April 16, 2015
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: James McSwiggen, Bharat Chowrira, Leonid Beigelman, Dennis Macejak, Shawn Zinnen, Pamela Pavco, Peter Haeberli, David Morrissey, Kathy Fosnaugh, Sharon F. Jamison, Nassim Usman, James Thompson, Chandra Vargeese, Weimin Wang, Tongqian Chen, Narendra K. Vaish
  • DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
    Publication number: 20150057373
    Abstract: Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: March 25, 2013
    Publication date: February 26, 2015
    Applicant: SIRNA THERAPEUTICS, INC
    Inventors: Matthew G. Stanton, Brian W. Budzik, Steven L. Colletti
  • Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides
    Patent number: 8901101
    Abstract: The present invention provides membrane lytic poly(amido amine) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: December 2, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Marina Busuek, Rubina G. Parmar, Michael Steven Poslusney, Weimin Wang, J. Michael Williams
  • Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications
    Patent number: 8877439
    Abstract: It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: November 4, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Gabor Butora, Ian W. Davies, William Michael Flanagan, Wenlang Fu, Denise M. Kenski, Ning Qi
  • RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
    Patent number: 8846894
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: September 30, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: James McSwiggen, Bharat Chowrira, Leonid Beigelman, Dennis Macejak, Shawn Zinnen, Pamela Pavco, Peter Haeberli, David Morrissey, Kathy Fosnaugh, Sharon F Jamison, Nassim Usman, James Thompson, Chandra Vargeese, Weimin Wang, Tongqian Chen, Narendra K Vaish
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20140288148
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: November 19, 2013
    Publication date: September 25, 2014
    Applicant: SIRNA THERAPEUTICS INC
    Inventors: Leonid Beigelman, James McSwiggen
  • RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
    Patent number: 8835623
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY
    Publication number: 20140235872
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: April 29, 2014
    Publication date: August 21, 2014
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Brian W. BUDZIK, Steven L. COLLETTI, Jennifer R. DAVIS, Ivory D. HILLS, Darla Danile SEIFRIED, Matthew G. STANTON
  • Amino alcohol cationic lipids for oligonucleotide delivery
    Patent number: 8802863
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that is more efficacious than traditional cationic lipids. The present invention employs amino alcohols to enhance the efficiency of in vivo delivery of siRNA.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: August 12, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Brian W. Budzik, Steven L. Colletti, Darla Danile Seifried, Matthew G. Stanton, Lu Tian
  • Low molecular weight cationic lipids for oligonucleotide delivery
    Patent number: 8748667
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: June 10, 2014
    Assignee: SIRNA Therapeutics, Inc.
    Inventors: Brian W. Budzik, Steven L. Colletti, Jennifer R. Davis, Ivory D. Hills, Darla Danile Seifried, Matthew G. Stanton
  • Conjugates and compositions for cellular delivery
    Patent number: 8461313
    Abstract: This invention features conjugates, compositions, methods of synthesis, and applications thereof, including folate derived conjugates of nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids and antisense nucleic acid molecules.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: June 11, 2013
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Jasenka Matulic-Adamic, Leonid Beigelman